Differential effects of D-amphetamine on red and blue light-induced photic activation: A novel BOLD fMRI assay of human dopamine function

Synapse

Volumn 62, Issue 4, 2008, Pages 268-272

  Cowan, Ronald L ^a   Wood, Julia ^a   Dietrich, Mary S ^a   Frederick, Blaise De B ^b,c   Lukas, Scott E ^b,c   Renshaw, Perry F ^b,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b MCLEAN HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Monoamine; Vision; Visual cortex

Indexed keywords

BRAIN MONOAMINE; DEXAMPHETAMINE; DOPAMINE; NEUROTRANSMITTER;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BLUE LIGHT; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHOTOSTIMULATION; PRIORITY JOURNAL; RED LIGHT; SCHIZOPHRENIA; SUBSTANCE ABUSE; SYNAPSE; VISUAL CORTEX; VISUAL SYSTEM;

ADULT; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; DOPAMINE; FEMALE; HUMANS; LIGHT; MAGNETIC RESONANCE IMAGING; MALE; PHOTIC STIMULATION; VISUAL CORTEX;

EID: 40549092315     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20491     Document Type: Article

References (24)

1. Ackerman JM, White FJ. 1992. Decreased activity of rat A10 dopamine neurons following withdrawal from repeated cocaine. Eur J Pharmacol 218:171-173.
2. American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association.
3. Asghar SJ, Tanay VA, Baker GB, Greenshaw A, Silverstone PH. 2003. Relationship of plasma amphetamine levels to physiological, subjective, cognitive and biochemical measures in healthy volunteers. Hum Psychopharmacol 18:291-299.
4. Banaschewski T, Ruppert S, Tannock R, Albrecht B, Becker A, Uebel H, Sergeant JA, Rothenberger A. 2006. Colour perception in ADHD. J Child Psychol Psychiatry 47:568-572.
5. Berger B, Gaspar P, Verney C. 1991. Dopaminergic innervation of the cerebral cortex: Unexpected differences between rodents and primates. Trends Neurosci 14:21-27.
6. Cowan RL, Haga E, deB Frederick B, Dietrich MS, Vimal RL, Lukas SE, Renshaw PF. 2006. MDMA use is associated with increased spatial BOLD fMRI visual cortex activation in human MDMA users. Pharmacol Biochem Behav 84:219-228.
7. Desai P, Roy M, Roy A, Brown S, Smelson D. 1997. Impaired color vision in cocaine-withdrawn patients. Arch Gen Psychiatry 54:696-699.
8. Di Forti M, Lappin JM, Murray RM. 2007. Risk factors for schizophrenia - All roads lead to dopamine. Eur Neuropsychopharmacol 17 (Suppl. 2):S101-S107.
9. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. 2007. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47:681-698.
10. Funk D, Marinelli PW, Le AD. 2006. Biological processes underlying co-use of alcohol and nicotine: Neuronal mechanisms, cross-tolerance, and genetic factors. Alcohol Res Health 29:186-192.
11. Girault JA, Greengard P. 2004. The neurobiology of dopamine signaling. Arch Neurol 61:641-644.
12. Gouras P, Zrenner E. 1981. Color coding in primate retina. Vision Res 21:1591-1598.
13. Haug BA, Kolle RU, Trenkwalder C, Oertel WH, Paulus W. 1995. Predominant affection of the blue cone pathway in Parkinson's disease. Brain 118 (Part 3):771-778.
14. Jain S, Kyriakides M, Silverstone T, Turner P. 1980. The effect of small and moderate doses of D-amphetamine on hunger, mood, and arousal in man. Psychopharmacology (Berl) 70: 109-111.
15. Krimer LS, Muly EC, Williams GV, Goldman-Rakic PS. 1998. Dopaminergic regulation of cerebral cortical microcirculation. Nat Neurosci 1:286-289.
16. Kwong KK, Belliveau JW, Chesler DA, Goldberg IE, Weisskoff RM, Poncelet BP, Kennedy DN, Hoppel BE, Cohen MS, Turner R, Cheng H-M, Brady TJ, Rosen BR. 1992. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Natl Acad Sci USA 89:5675-5679.
17. Lebel M, Robinson P, Cyr M. 2007. Canadian Association of Neurosciences Review: The role of dopamine receptor function in neurodegenerative diseases. Can J Neurol Sci 34:18-29.
18. Logothetis NK, Pfeuffer J. 2004. On the nature of the BOLD fMRI contrast mechanism. Magn Reson Imaging 22:1517-1531.
19. Mrzljak L, Bergson C, Pappy M, Huff R, Levenson R, Goldman-Rakic PS. 1996. Localization of dopamine D4 receptors in GABAergic neurons of the primate brain. Nature 381:245-248.
20. Nguyen-Legros J, Versaux-Botteri C, Vernier P. 1999. Dopamine receptor localization in the mammalian retina. Mol Neurobiol 19:181-204.
21. Parrish TB, Gitelman DR, LaBar KS, Mesulam MM. 2000. Impact of signal-to-noise on functional MRI. Magn Reson Med 44:925-932.
22. Roy M, Smelson DA, Roy A. 1996. Abnormal electroretinogram in cocaine-dependent patients. Relationship to craving. Br J Psychiatry 168:507-511.
23. Self DW, Nestler EJ. 1995. Molecular mechanisms of drug reinforcement and addiction. Annu Rev Neurosci 18:463-495.
24. Swanson JM, Kinsbourne M, Nigg J, Lanphear B, Stefanatos GA, Volkow N, Taylor E, Casey BJ, Castellanos FX, Wadhwa PD. 2007. Etiologic subtypes of attention-deficit/hyperactivity disorder: Brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychol Rev 17:39-59.